Biggest News Aggregation in the World
📰 Accepted News

Page 45 - Accepted News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Accepted. Real-time updates on events, politics, business and more.

Manipal's AUA - Back to campus and welcoming New Fall 2022 Students

Bangalore (Karnataka) [India], August 26 (ANI/PRNewswire): Come fall and the campus of Manipal's American University of Antigua is once again beaming vibrantly with the chatter of the New Fall 2022 students from diverse ethnicities. This is a special welcome, as the campus comes alive after the pandemic cast an unexpected spell of silence for almost more than two long years. This fall has welcomed the batch of aspiring global doctors, who have begun their medical education journey at the Man...
United States United Kingdom Antigua And Barbuda York State Education Department Manipal American University Of Antigua National Medical Council Of India

Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV)
United States Catalina Loveman Christine Chiou Hidradenitis Suppurativa Jim Lee European Academy Of Dermatology

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Jaguar Health, Inc.: Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder Has Been Accepted for Review

Microvillus Inclusion Disease (MVID), a CDD, Is a Life-Threatening and Rare Autosomal Recessive Disease That Affects Newborns and Children and Leads to Significant Morbidity and Mortality From Severe Secretory
United Arab Emirates United States Martire Particco Lisa Conte Peter Hodge Jaguar Health

Menarini Industrie Farmaceutiche Riunite: Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2-
United States France General Kostenloser Wertpapierhandel Elcin Barker Ergun Menarini Group European Union

The Menarini Group and its Subsidiary Stemline Therapeutics: Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced
United States France General Valeria Speroni Cardi Ashani Lewis Elcin Barker Ergun Menarini Group

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science